These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35221289)

  • 1. Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Alhamadani F; Zhang K; Parikh R; Wu H; Rasmussen TP; Bahal R; Zhong XB; Manautou JE
    Drug Metab Dispos; 2022 Jun; 50(6):879-887. PubMed ID: 35221289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Migliorati JM; Liu S; Liu A; Gogate A; Nair S; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
    Drug Metab Dispos; 2022 Jun; 50(6):888-897. PubMed ID: 35221287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of survivin by 2'-
    Li Y; Chen S; Rahimizadeh K; Zhang Z; Veedu RN
    RSC Adv; 2024 Apr; 14(19):13336-13341. PubMed ID: 38660533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Sang A; Zhuo S; Bochanis A; Manautou JE; Bahal R; Zhong XB; Rasmussen TP
    BioDrugs; 2024 Jul; 38(4):511-526. PubMed ID: 38914784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination.
    Yu AM; Tu MJ
    Pharmacol Ther; 2022 Feb; 230():107967. PubMed ID: 34403681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO.
    Sabrina Haque U; Kohut M; Yokota T
    Curr Res Toxicol; 2024; 7():100182. PubMed ID: 38983605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity of marketed antisense oligonucleotide drugs.
    Wu H; Wahane A; Alhamadani F; Zhang K; Parikh R; Lee S; McCabe EM; Rasmussen TP; Bahal R; Zhong XB; Manautou JE
    Curr Opin Toxicol; 2022 Dec; 32():. PubMed ID: 37193356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
    Barresi V; Musmeci C; Rinaldi A; Condorelli DF
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
    Hwang J; Yokota T
    Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
    Latham BD; Geffert RM; Jackson KD
    Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics.
    Ramasamy T; Ruttala HB; Munusamy S; Chakraborty N; Kim JO
    J Control Release; 2022 Dec; 352():861-878. PubMed ID: 36397636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Evaluation of Exon 51 Skipping in hDMD/Dmd-null Mice.
    Sheri N; Yokota T
    Methods Mol Biol; 2023; 2640():327-336. PubMed ID: 36995605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA-approved drug labeling for the study of drug-induced liver injury.
    Chen M; Vijay V; Shi Q; Liu Z; Fang H; Tong W
    Drug Discov Today; 2011 Aug; 16(15-16):697-703. PubMed ID: 21624500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
    Chen S; Heendeniya SN; Le BT; Rahimizadeh K; Rabiee N; Zahra QUA; Veedu RN
    BioDrugs; 2024 Mar; 38(2):177-203. PubMed ID: 38252341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in the Tolerability Profile of 2'-
    Partridge W; Xia S; Kwoh TJ; Bhanot S; Geary RS; Baker BF
    Nucleic Acid Ther; 2021 Dec; 31(6):417-426. PubMed ID: 34242101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligonucleotide Enhancing Compound Increases Tricyclo-DNA Mediated Exon-Skipping Efficacy in the Mdx Mouse Model.
    Bizot F; Fayssoil A; Gastaldi C; Irawan T; Phongsavanh X; Mansart A; Tensorer T; Brisebard E; Garcia L; Juliano RL; Goyenvalle A
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update.
    Sheikh O; Yokota T
    Arch Toxicol; 2022 Jan; 96(1):1-9. PubMed ID: 34797383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JCL roundtable: Risk evaluation and mitigation strategy.
    Brown WV; Bramlet DA; Ross JL; Underberg JA
    J Clin Lipidol; 2016; 10(6):1288-1296. PubMed ID: 27919344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy.
    López-Martínez A; Soblechero-Martín P; Arechavala-Gomeza V
    Methods Mol Biol; 2022; 2434():217-233. PubMed ID: 35213020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.